As I think about the current healthcare system and all of its strong attributes, it is hard to overlook the fact that it also is fragmented, disjointed and laced with high price tags. This week, several stories focused on how to work toward a more cost-efficient, patient centric-based system. I cant help but revert back to the 1970s Brotherhood of Man classic "United We Stand" and think that perhaps this is the mantra those in the healthcare system must stand behind: United we stand, divided we fall.

Iodine-131 is lauded for its specificity in targeting thyroid lesions. Yet, some experts are debating whether the treatment should be used across the board or stratified.

While whole-body oncology imaging advances are still emerging, the best modality remains to be seen.

In 2011, the FDA cleared I-123 ioflupane for dopamine transporter imaging, and an SNM expert provides coding advice for Parkinsonian syndromes.

Advancements in molecular neuroimaging are providing new ways to assess neuroinflammation in the brain.

Differences in dopamine responsivity, identified using PET imaging, have been linked to variation in human choice behavior, specifically the drive to work harder for larger rewards, according to a study published May 2 in the Journal of Neuroscience.

With the aging population, the proliferation of neurodegenerative diseases, particularly Alzheimers, is becoming a truly global burden.

Paul H. Ellenbogen, MD, was elected chair of the American College of Radiology (ACR) board of chancellors.